{
    "ticker": "TNXP",
    "name": "Tonix Pharmaceuticals Holding Corp.",
    "description": "Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders and pain. Founded in 2012 and headquartered in Chatham, New Jersey, Tonix is dedicated to addressing significant unmet medical needs through its proprietary product candidates. The company's lead candidate, TNX-102 SL, is being investigated for the treatment of fibromyalgia and other pain-related conditions. Tonix is also developing TNX-601 CR, a novel formulation of a previously marketed CNS drug, for the treatment of major depressive disorder and post-traumatic stress disorder (PTSD). With a strong emphasis on research and development, Tonix aims to leverage its expertise in pharmacology and formulation development to bring new therapies to market. The company is committed to advancing healthcare through scientific innovation and collaboration with regulatory agencies, academic institutions, and industry partners. Tonix Pharmaceuticals is actively working to expand its pipeline, focusing on both CNS and immunology indications, and strives to improve the quality of life for patients suffering from debilitating conditions.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Chatham, New Jersey, USA",
    "founded": "2012",
    "website": "https://www.tonixpharma.com",
    "ceo": "Seth Lederman",
    "social_media": {
        "twitter": "https://twitter.com/TonixPharma",
        "linkedin": "https://www.linkedin.com/company/tonix-pharmaceuticals/"
    },
    "investor_relations": "https://investors.tonixpharma.com",
    "key_executives": [
        {
            "name": "Seth Lederman",
            "position": "CEO"
        },
        {
            "name": "Elizabeth L. A. C. H. H. W. H. J. M. Brown",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "CNS Disorders",
            "products": [
                "TNX-102 SL",
                "TNX-601 CR"
            ]
        },
        {
            "category": "Immunology",
            "products": [
                "TNX-801"
            ]
        }
    ],
    "seo": {
        "meta_title": "Tonix Pharmaceuticals Holding Corp. | Innovative CNS Treatments",
        "meta_description": "Tonix Pharmaceuticals Holding Corp. focuses on developing new therapies for CNS disorders and pain. Explore our innovative pipeline and commitment to patient care.",
        "keywords": [
            "Tonix Pharmaceuticals",
            "CNS Disorders",
            "Fibromyalgia",
            "Biopharmaceuticals",
            "TNX-102 SL",
            "TNX-601 CR"
        ]
    },
    "faq": [
        {
            "question": "What is Tonix Pharmaceuticals focused on?",
            "answer": "Tonix Pharmaceuticals is focused on developing innovative treatments for CNS disorders and pain-related conditions."
        },
        {
            "question": "Who is the CEO of Tonix Pharmaceuticals?",
            "answer": "Seth Lederman is the CEO of Tonix Pharmaceuticals Holding Corp."
        },
        {
            "question": "Where is Tonix Pharmaceuticals headquartered?",
            "answer": "Tonix Pharmaceuticals is headquartered in Chatham, New Jersey, USA."
        },
        {
            "question": "What are Tonix's main product candidates?",
            "answer": "Tonix's main product candidates include TNX-102 SL for fibromyalgia and TNX-601 CR for major depressive disorder and PTSD."
        },
        {
            "question": "When was Tonix Pharmaceuticals founded?",
            "answer": "Tonix Pharmaceuticals was founded in 2012."
        }
    ],
    "competitors": [
        "PTGX",
        "SAGE",
        "AXSM",
        "AVTX"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "MRK",
        "BMY"
    ]
}